219 related articles for article (PubMed ID: 19462209)
41. Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.
Honndorf VS; Wiehr S; Rolle AM; Schmitt J; Kreft L; Quintanilla-Martinez L; Kohlhofer U; Reischl G; Maurer A; Boldt K; Schwarz M; Schmidt H; Pichler BJ
Oncotarget; 2016 May; 7(19):28247-61. PubMed ID: 27070087
[TBL] [Abstract][Full Text] [Related]
42. Visualisation of neuroblastoma growth in a Scid mouse model using [18F]FDG and [18F]FLT-PET.
Krieger-Hinck N; Gustke H; Valentiner U; Mikecz P; Buchert R; Mester J; Schumacher U
Anticancer Res; 2006; 26(5A):3467-72. PubMed ID: 17094468
[TBL] [Abstract][Full Text] [Related]
43. Comparison of 18F-fluoro-deoxy-glucose, 18F-fluoro-methyl-choline, and 18F-DPA714 for positron-emission tomography imaging of leukocyte accumulation in the aortic wall of experimental abdominal aneurysms.
Sarda-Mantel L; Alsac JM; Boisgard R; Hervatin F; Montravers F; Tavitian B; Michel JB; Le Guludec D
J Vasc Surg; 2012 Sep; 56(3):765-73. PubMed ID: 22726755
[TBL] [Abstract][Full Text] [Related]
44. An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.
Keen H; Pichler B; Kukuk D; Duchamp O; Raguin O; Shannon A; Whalley N; Jacobs V; Bales J; Gingles N; Ricketts SA; Wedge SR
Mol Imaging Biol; 2012 Jun; 14(3):355-65. PubMed ID: 21761255
[TBL] [Abstract][Full Text] [Related]
45. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
[TBL] [Abstract][Full Text] [Related]
46. Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.
Habibollahi P; van den Berg NS; Kuruppu D; Loda M; Mahmood U
J Nucl Med; 2013 Feb; 54(2):252-8. PubMed ID: 23376854
[TBL] [Abstract][Full Text] [Related]
47. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
Wagner M; Seitz U; Buck A; Neumaier B; Schultheiss S; Bangerter M; Bommer M; Leithäuser F; Wawra E; Munzert G; Reske SN
Cancer Res; 2003 May; 63(10):2681-7. PubMed ID: 12750297
[TBL] [Abstract][Full Text] [Related]
48. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.
Leyton J; Latigo JR; Perumal M; Dhaliwal H; He Q; Aboagye EO
Cancer Res; 2005 May; 65(10):4202-10. PubMed ID: 15899811
[TBL] [Abstract][Full Text] [Related]
49. [The use of 18F-fluorothymidine and 18F-fluorocholine in imaging with positron emission tomography].
Skoura E; Datseris IE
Hell J Nucl Med; 2010; 13(1):88-90. PubMed ID: 20411184
[TBL] [Abstract][Full Text] [Related]
50. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
[TBL] [Abstract][Full Text] [Related]
51. [18F]FLT-PET in oncology: current status and opportunities.
Been LB; Suurmeijer AJ; Cobben DC; Jager PL; Hoekstra HJ; Elsinga PH
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1659-72. PubMed ID: 15565331
[TBL] [Abstract][Full Text] [Related]
52. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
53. Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
Lee SJ; Kang HY; Kim SY; Chung JH; Oh SJ; Ryu JS; Kim SB; Kang JS; Park SK; Kim HM; Kim MH; Moon DH
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1436-48. PubMed ID: 21484374
[TBL] [Abstract][Full Text] [Related]
54. 18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.
Chang E; Liu H; Unterschemmann K; Ellinghaus P; Liu S; Gekeler V; Cheng Z; Berndorff D; Gambhir SS
Clin Cancer Res; 2015 Jan; 21(2):335-46. PubMed ID: 25381339
[TBL] [Abstract][Full Text] [Related]
55. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
56. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
57. [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.
Zhang CC; Yan Z; Li W; Kuszpit K; Painter CL; Zhang Q; Lappin PB; Nichols T; Lira ME; Affolter T; Fahey NR; Cullinane C; Spilker M; Zasadny K; O'Brien P; Buckman D; Wong A; Christensen JG
Clin Cancer Res; 2012 Mar; 18(5):1303-12. PubMed ID: 22170262
[TBL] [Abstract][Full Text] [Related]
58. 18F-fluorodeoxythymidine micro-positron-emission tomography versus 18F-fluorodeoxyglucose micro-positron-emission tomography for in vivo minimal residual disease imaging.
Ekshyyan O; Sibley D; Caldito GC; Sunderland J; Vascoe C; Nathan CA
Laryngoscope; 2013 Jan; 123(1):107-11. PubMed ID: 23018799
[TBL] [Abstract][Full Text] [Related]
59. Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.
Herrmann K; Buck AK
PET Clin; 2014 Jul; 9(3):331-8. PubMed ID: 25030396
[TBL] [Abstract][Full Text] [Related]
60. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
